Vivo Capital
Palo Alto · Series A–Series C
Fund manager profile
Vivo Capital is a venture fund manager based in Palo Alto. SEC filings show 0 venture funds on record, most recently undefined filed .
Source: SEC EDGAR Form D filings. Firm website data not yet available.
What they invest in
from 13 of 88 portfolio companiesBiotech ×10Medical Devices ×10Healthtech ×9Digital Health ×2Enterprise Software ×2SaaS ×2AI & Machine Learning ×1Deep Tech ×1
HQs:United States×3Australia×1Denmark×1
Investments · showing 60 of 88
founders shown can be your intro pathAscendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases. The company focuses on long-acting therapeutic formulations to address endocrine and rare disease indications.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
BiotechHealthtechMedical Devices
Ossium Health develops cellular therapies and bioengineered products for clinical use, leveraging adult stem cell technologies and advanced cell processing platforms. The company operates as a clinical-stage biotech firm manufacturing and distributing cellular therapeutics for patients with organ and tissue diseases.
BiotechHealthtechMedical Devices
Kevin Caldwell(CEO, Co-Founder & President)Dr. Woods(Chief Science Officer, Co-Founder, EVP, CLIA Laboratory Director)
Pharmaceutical company developing medicines and vaccines for patient health and treatment. Operating for over 130 years with focus on clinical research and drug development.
BiotechHealthtech
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical Devices
Michael Kavanaugh(Founding Advisor)
HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories. The company serves biomedical researchers, pharmaceutical companies, and diagnostic labs with automated histology processing and pathology consultation.
AI & Machine LearningBiotechHealthtechMedical DevicesNew York City, US
Ke Cheng(Founder/CEO)inLinh Hoang(Chief Executive Officer)Jerry Kuang(Chief Operations Officer)Julie Feldstein(Chief Pathologist)
Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
BiotechMedical Devices
Magnolia Medical develops the Steripath® platform, an FDA-cleared medical device designed to reduce blood culture contamination and improve diagnostic accuracy for sepsis testing in hospital settings. The solution is used by hospitals and healthcare systems to enhance clinical decision-making and patient outcomes.
Digital HealthHealthtechMedical Devices
RayzeBio develops radiopharmaceutical therapies for cancer treatment. The company is a subsidiary of Bristol Myers Squibb focused on advancing targeted cancer therapies to patients.
BiotechHealthtechMedical Devices
Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)
Frequently asked questions
- What stage does Vivo Capital invest at?
- Vivo Capital invests at the Series A, Series B, Series C stages.
- Where is Vivo Capital located?
- Vivo Capital is headquartered in Palo Alto, US.
Similar investors
3TS Capital is a technology investment firm with over 25 years of experience managing multiple fund generations. The firm partners with exceptional founders to scale internationally, targeting high-growth SMEs that are either proven local leaders or innovative global challengers.
500 Global's Sustainable Growth practice designs and implements sovereign-aligned strategies that unlock resilient, inclusive, and sustainable economic growth across the Global Majority—Asia, Africa, Latin America, and the Middle East. The practice bridges public priorities and private capital through ecosystem development, blended finance, and localized innovation programs addressing health, agriculture, gender, climate, and education.
83North is a lean venture capital partnership of four equal general partners that has operated for 19 years. The firm invests globally across the US, Europe, and Israel, and in 2025 raised what it describes as its final fund, shifting focus toward selectively pursuing new opportunities while supporting existing portfolio companies.
a16z is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz that invests in seed through growth-stage technology companies across multiple sectors including AI, healthcare, consumer, crypto, enterprise, fintech, and gaming. The firm manages over $100 billion in assets and operates a distinctive platform model with a large team of operators supporting founders throughout their journey.
August Capital is a venture capital firm headquartered in the San Francisco Bay Area that has invested in early-stage startups across information technology since 1995. The firm manages approximately $2 billion in assets and combines capital deployment with operational support and networking assistance to help entrepreneurs build successful companies.